Silence Therapeutics plc

SLN

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001479615

None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $131.4M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data not computable: dilution, distress, fortress balance sheet
Inputs computable	4 of 13
Graded from	filings received through Mar 5, 2026 260 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$19.82 2026-11-19; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a biotechnology company focused on discovering and developing novel molecules incorporating short interfering ribonucleic acid, or siRNA, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Our siRNA molecules are designed to harness the body's natural mechanism of RNAi by specifically binding to and degrading messenger RNA, or mRNA, molecules that encode specific targeted disease-associated proteins in a cell. By degrading the message that encodes the disease-associated protein, the production of that protein is reduced and its level of activity is lowered.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 60.0						
Gross profitability	0.3%	32.8%		93.3	346	2025-12-31
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(15.8%)	(6.7%)	26.6	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 2					
Solvency, sleeve percentile 43.7					
Altman Z double-prime	(12.42)	0.31	67.0	705	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	8.72x	2.68x	20.4	781	2025-12-31
Growth and financing					
Revenue growth, three-year compound	not computable	9.6%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	33.9%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	not computable	3.2%			
four annual observations are required; found 2					
Net share issuance, one year	not computable	1.6%			
firm-wide XBRL shares cannot be assigned to one ticker class					

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	4 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	52.7%	(1.7%)	81
Distance from 52-week high	(0.1%)	(31.7%)	99
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	not computable	0.6%	
Book value to price	not computable	0.29	
Sales to price	not computable	0.37	
Composite equity issuance, five years	not computable	13.5%	
Relative strength against the sector, log excess return	0.25	(0.19)	81
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$247.7M
Operating cash flow, four quarters	-$44.1M
Months of runway	67.3
Days since last periodic filing	7 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$12.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$344,000	2025-12-31	2026-03-05	10-K	26-092591
2	assets	us-gaap:Assets	$131.4M	2025-12-31	2026-03-05	10-K	26-092591
3	net income	us-gaap:NetIncomeLoss	-$88.6M	2025-12-31	2026-03-05	10-K	26-092591
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$62.3M	2025-12-31	2026-03-05	10-K	26-092591
5	assets	us-gaap:Assets	$202.6M	2024-12-31	2026-03-05	10-K	26-092591
6	current assets	us-gaap:AssetsCurrent	$118.7M	2025-12-31	2026-03-05	10-K	26-092591
7	current liabilities	us-gaap:LiabilitiesCurrent	$13.6M	2025-12-31	2026-03-05	10-K	26-092591
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$562.6M	2025-12-31	2026-03-05	10-K	26-092591
9	operating income	us-gaap:OperatingIncomeLoss	-$91.1M	2025-12-31	2026-03-05	10-K	26-092591
10	book equity	us-gaap:StockholdersEquity	$62.3M	2025-12-31	2026-03-05	10-K	26-092591
11	liabilities	us-gaap:Liabilities	$69.1M	2025-12-31	2026-03-05	10-K	26-092591
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$559,000	2025-12-31	2026-03-05	10-K	26-092591
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$43.3M	2024-12-31	2026-03-05	10-K	26-092591
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$55,000	2025-12-31	2026-03-05	10-K	26-092591
15	depreciation amortization	us-gaap:Depreciation	$312,000	2025-12-31	2026-03-05	10-K	26-092591
16	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$88.6M	2025-12-31	2026-03-05	10-K	26-092591
17	income tax	us-gaap:IncomeTaxExpenseBenefit	$11,000	2025-12-31	2026-03-05	10-K	26-092591
18	current assets	us-gaap:AssetsCurrent	$187.4M	2024-12-31	2026-03-05	10-K	26-092591
19	current liabilities	us-gaap:LiabilitiesCurrent	$16.8M	2024-12-31	2026-03-05	10-K	26-092591

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.